The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
Chaitra Ujjani, 1 Anthony Mato, 2 Brian T Hill, 3 John N Allan, 4 Erick Lansigan, 5 Ryan Jacobs, 6 Hande Tuncer, 7 John Pagel, 8 Danielle Brander, 9 Bruce Cheson, 10 Paul Barr, 11 Lindsey E Roeker, 2 Jeffrey Pu, 12 Nirav N Shah, 13 Andre Goy, 14 Stephen J Schuster, 15 Nicole Lamanna, 16 Alison Sehga...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/55e83f385ab34228a9f4be53365dc63d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:55e83f385ab34228a9f4be53365dc63d |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:55e83f385ab34228a9f4be53365dc63d2021-12-02T10:53:11ZThe Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy1179-9889https://doaj.org/article/55e83f385ab34228a9f4be53365dc63d2020-08-01T00:00:00Zhttps://www.dovepress.com/the-impact-of-age-on-survival-in-cll-patients-receiving-ibrutinib-as-i-peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889Chaitra Ujjani, 1 Anthony Mato, 2 Brian T Hill, 3 John N Allan, 4 Erick Lansigan, 5 Ryan Jacobs, 6 Hande Tuncer, 7 John Pagel, 8 Danielle Brander, 9 Bruce Cheson, 10 Paul Barr, 11 Lindsey E Roeker, 2 Jeffrey Pu, 12 Nirav N Shah, 13 Andre Goy, 14 Stephen J Schuster, 15 Nicole Lamanna, 16 Alison Sehgal, 17 Constantine S Tam, 18 Mazyar Shadman 1 1Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 2Division of Hematological Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 3Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA; 4Division of Hematology and Medical Oncology, New York Presbyterian & Weill Cornell, New York, NY, USA; 5Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA; 6Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC, USA; 7Lowell General Hospital, Tufts Medical Center, Boston, MA, USA; 8Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA; 9Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA; 10Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA; 11Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA; 12Division of Hematology/Oncology, SUNY Upstate Medical University, Syracuse, NY, USA; 13Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; 14John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; 15Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; 16Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA; 17University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 18Peter McCallum Cancer Centre, University of Melbourne, East Melbourne, VI, AustraliaCorrespondence: Chaitra UjjaniSeattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, 825 Eastlake Ave E, Mail Stop CE3-300, Seattle, WA, USATel +1 206-606-1955Fax +1 206-606-1130Email ujjani@uw.eduIntroduction: Recent randomized trials have demonstrated the efficacy of ibrutinib-based therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected number of unexplained deaths were reported with front-line ibrutinib in a patient population aged at least 65 years compared to ECOG 1912, which included patients up to 70 years of age.Methods: Therefore, we conducted a retrospective analysis to investigate whether ibrutinib was associated with a greater mortality in older patients outside of a clinical trial setting. This multicenter analysis was performed by investigators at 20 academic and community practices.Results: Amongst the 391 patients included, there was no correlation between age and response rate, PFS, or OS. However, there was a trend to higher rate of deaths in patients > 65-years-old (8.7% vs 3.8%, p=0.097), with an increased number of early deaths (13 vs 4, p=0.3).Conclusion: These data suggest greater intolerance, and possibly mortality, with ibrutinib in an older population. Patients should be educated regarding the potential complications related to ibrutinib and symptoms of concern to report.Keywords: CLL, ibrutinib, elderlyUjjani CMato AHill BTAllan JNLansigan EJacobs RTuncer HPagel JBrander DCheson BBarr PRoeker LEPu JShah NNGoy ASchuster SJLamanna NSehgal ATam CSShadman MDove Medical PressarticlecllibrutinibelderlyDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol Volume 10, Pp 1-5 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
cll ibrutinib elderly Diseases of the blood and blood-forming organs RC633-647.5 |
| spellingShingle |
cll ibrutinib elderly Diseases of the blood and blood-forming organs RC633-647.5 Ujjani C Mato A Hill BT Allan JN Lansigan E Jacobs R Tuncer H Pagel J Brander D Cheson B Barr P Roeker LE Pu J Shah NN Goy A Schuster SJ Lamanna N Sehgal A Tam CS Shadman M The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy |
| description |
Chaitra Ujjani, 1 Anthony Mato, 2 Brian T Hill, 3 John N Allan, 4 Erick Lansigan, 5 Ryan Jacobs, 6 Hande Tuncer, 7 John Pagel, 8 Danielle Brander, 9 Bruce Cheson, 10 Paul Barr, 11 Lindsey E Roeker, 2 Jeffrey Pu, 12 Nirav N Shah, 13 Andre Goy, 14 Stephen J Schuster, 15 Nicole Lamanna, 16 Alison Sehgal, 17 Constantine S Tam, 18 Mazyar Shadman 1 1Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 2Division of Hematological Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 3Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA; 4Division of Hematology and Medical Oncology, New York Presbyterian & Weill Cornell, New York, NY, USA; 5Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA; 6Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC, USA; 7Lowell General Hospital, Tufts Medical Center, Boston, MA, USA; 8Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA; 9Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA; 10Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA; 11Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA; 12Division of Hematology/Oncology, SUNY Upstate Medical University, Syracuse, NY, USA; 13Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; 14John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; 15Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; 16Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA; 17University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 18Peter McCallum Cancer Centre, University of Melbourne, East Melbourne, VI, AustraliaCorrespondence: Chaitra UjjaniSeattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, 825 Eastlake Ave E, Mail Stop CE3-300, Seattle, WA, USATel +1 206-606-1955Fax +1 206-606-1130Email ujjani@uw.eduIntroduction: Recent randomized trials have demonstrated the efficacy of ibrutinib-based therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected number of unexplained deaths were reported with front-line ibrutinib in a patient population aged at least 65 years compared to ECOG 1912, which included patients up to 70 years of age.Methods: Therefore, we conducted a retrospective analysis to investigate whether ibrutinib was associated with a greater mortality in older patients outside of a clinical trial setting. This multicenter analysis was performed by investigators at 20 academic and community practices.Results: Amongst the 391 patients included, there was no correlation between age and response rate, PFS, or OS. However, there was a trend to higher rate of deaths in patients > 65-years-old (8.7% vs 3.8%, p=0.097), with an increased number of early deaths (13 vs 4, p=0.3).Conclusion: These data suggest greater intolerance, and possibly mortality, with ibrutinib in an older population. Patients should be educated regarding the potential complications related to ibrutinib and symptoms of concern to report.Keywords: CLL, ibrutinib, elderly |
| format |
article |
| author |
Ujjani C Mato A Hill BT Allan JN Lansigan E Jacobs R Tuncer H Pagel J Brander D Cheson B Barr P Roeker LE Pu J Shah NN Goy A Schuster SJ Lamanna N Sehgal A Tam CS Shadman M |
| author_facet |
Ujjani C Mato A Hill BT Allan JN Lansigan E Jacobs R Tuncer H Pagel J Brander D Cheson B Barr P Roeker LE Pu J Shah NN Goy A Schuster SJ Lamanna N Sehgal A Tam CS Shadman M |
| author_sort |
Ujjani C |
| title |
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy |
| title_short |
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy |
| title_full |
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy |
| title_fullStr |
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy |
| title_full_unstemmed |
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy |
| title_sort |
impact of age on survival in cll patients receiving ibrutinib as initial therapy |
| publisher |
Dove Medical Press |
| publishDate |
2020 |
| url |
https://doaj.org/article/55e83f385ab34228a9f4be53365dc63d |
| work_keys_str_mv |
AT ujjanic theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT matoa theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT hillbt theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT allanjn theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT lansigane theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT jacobsr theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT tuncerh theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT pagelj theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT branderd theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT chesonb theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT barrp theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT roekerle theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT puj theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT shahnn theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT goya theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT schustersj theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT lamannan theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT sehgala theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT tamcs theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT shadmanm theimpactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT ujjanic impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT matoa impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT hillbt impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT allanjn impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT lansigane impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT jacobsr impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT tuncerh impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT pagelj impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT branderd impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT chesonb impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT barrp impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT roekerle impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT puj impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT shahnn impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT goya impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT schustersj impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT lamannan impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT sehgala impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT tamcs impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy AT shadmanm impactofageonsurvivalincllpatientsreceivingibrutinibasinitialtherapy |
| _version_ |
1718396529898684416 |